ArticleAnnals of internal medicine2021

In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney disease, or CV or renal mortality.

Donald A Molony et al.PubMed ↗Publisher ↗

No numbers read from the abstract.